Supporting Information

Direct Copper-Catalyzed Amination of sp² C-H Bonds

Ly Dieu Tran, James Roane, and Olafs Daugulis*

Department of Chemistry, University of Houston, Houston, Texas 77204-5003, United States

Table of Contents

GENERAL CONSIDERATIONS	2
MATERIALS	2
SYNTHESIS OF AMIDES	2
OPTIMIZATION OF REACTION CONDITIONS	
AMINATION OF BENZOIC ACID DERIVATIES	9
AMINATION OF BENZYLAMINE DERIVATIES	16
AMINATION OF PRIMARY AND SECONDARY AMINES	17
AUXILIARY CLEAVAGE	
CONTROL EXPERIMENTS	
REFERENCES	

GENERAL CONSIDERATIONS. Reactions were performed without special precautions to exclude air or moisture in 1-dram screw-cap vials equipped with Teflon[®] liners and a stir bar or using a 10 ml Kontes flask. Column chromatography was performed on 60 Å silica gel (Dynamic Adsorbents Inc). Purification by preparative HPLC was performed on a Shimadzu Prominence LC (LC-20AB) equipped with a SPD-20A UV-Vis detector and a Varian Dynamax (250 mm × 21.4 mm) column. ¹H, ¹³C and ¹⁹F NMR spectra were recorded on JEOL ECX-400 and JEOL ECX-500 spectrometers using TMS or residual solvent peak as a standard. Compounds for HRMS were analyzed by positive mode electrospray ionization (ESI) using Agilent 6530 QTOF mass spectrometer at the Mass Spectrometry Facility (MSF) of the Department of Chemistry & Biochemistry, University of Texas at Austin. IR-spectra were obtained using a Perkin Elmer Spectrum 100 FT-IR spectrometer. Preparative thin layer chromatography was performed on Analtech TLC plates (20 cm × 20 cm, 20 microns).

MATERIALS. The following starting materials were obtained from commercial sources and were used without further purification: 8-aminoquinoline, 4-fluorobenzoyl chloride, 4-methoxybenzoyl chloride, 4-*t*-butylbenzoyl chloride, monomethyl terephthalate, 3-methoxybenzoic acid, 2-trifluoromethylbenzoyl chloride, 2-naphthalenecarboxylic acid, 2-methylbenzoyl chloride, 2-methylnicotinic acid, 2-methyl-3-furancarboxylic acid, piconilic acid, ethyl chloroformate, cumylamine, 1-(4-fluorophenyl)-1-methylethylamine, pyrrolidine, cyclohexylamine, cyclooctylamine, N-methyl benzylamine, N-methyl propylamine, ethyl isonipecotate, 4-cyanopiperidine, 4-piperidone ethylene ketal, tert-butyl piperidin-4-ylcarbamate.

SYNTHESIS OF AMIDES



N-(4-Methoxybenzoyl)-8-aminoquinoline: 8-Aminoquinoline (2.17 g, 15 mmol) and triethylamine (2.8 mL, 20 mmol) were dissolved in anhydrous CH_2Cl_2 (40 mL) in a 100 ml round-bottom flask followed by dropwise addition of 4-methoxybenzoyl chloride (3.4 g, 20 mmol) through syringe. The reaction mixture was stirred overnight. After completion, the reaction was diluted with CH_2Cl_2 (50 mL), washed by aqueous HCl (15 mL, 1N), NaHCO₃ (15 mL of saturated aqueous solution), brine (25 mL), and dried over Na₂SO₄. The organic solvent was removed by evaporation. Purification by column chromatography in

toluene/ethyl acetate (30:1) afforded 3.86 g of pure amide (92%) as a white solid. This compound is known.¹ ¹H NMR (500 MHz, CDCl₃, ppm) δ 10.69 (*s*, 1H) 8.93 (*dd*, *J* = 7.4 Hz, *J* = 1.1 Hz, 1H) 8.85 (*dd*, *J* = 4.0 Hz, *J* = 1.7 Hz, 1H) 8.18 (*dd*, *J* = 8.6 Hz, *J* = 1.7 Hz, 1H) 8.09–8.04 (*m*, 2H) 7.59 (*t*, *J* = 8.0, 1H) 7.55–7.51 (*m*, 1H) 7.47 (*dd*, *J* = 4.6 Hz, *J* = 8.6 Hz, 1H) 7.07–7.01 (*m*, 2H) 3.89 (*s*, 3H).



N-(4-Fluorobenzoyl)-8-aminoquinoline: 8-Aminoquinoline (1.44 g, 10 mmol) and triethylamine (1.8 mL, 13 mmol) were dissolved in anhydrous CH₂Cl₂ (30 mL) in a 50 ml round-bottom flask followed by dropwise addition of 4-fluorobenzoyl chloride (2.06 g, 13.2 mmol) through syringe. The reaction mixture was stirred overnight. After completion, the reaction was diluted with CH₂Cl₂ (25 mL), washed by aqueous HCl (15 mL, 1N), NaHCO₃ (15 mL of saturated aqueous solution), brine (25 mL), and dried over Na₂SO₄. The organic solvent was removed by evaporation. Purification by column chromatography in toluene/ethyl acetate (20:1) afforded 2.56 g of pure amide (96%) as a light yellow solid. This compound is known.¹ ¹H NMR (500 MHz, CDCl₃, ppm) δ 10.86 (*s*, 1H) 8.87 (*d*, *J* = 8.0 Hz, 1H) 8.86 – 8.81 (*m*, 1H) 8.20–8.14 (*m*, 1H) 8.12–8.05 (*m*, 2H) 7.61–7.55 (*m*, 1H) 7.55–7.50 (*m*, 1H) 7.49–7.43 (*m*, 1H) 7.24–7.18 (*m*, 2H).



N-(4-*t*-Butylbenzoyl)-8-aminoquinoline: 8-Aminoquinoline (1.44 g, 10 mmol) and triethylamine (1.8 mL, 13 mmol) were dissolved in anhydrous CH_2Cl_2 (30 mL) in a 50 ml round-bottom flask followed by dropwise addition of 4-*t*-butylbenzoyl chloride (2.56 g, 13 mmol) through syringe. The reaction mixture was stirred overnight. After completion, the reaction was diluted with CH_2Cl_2 (25 mL), washed by aqueous HCl (15 mL, 1N), NaHCO₃ (15 mL of saturated aqueous solution), brine (25 mL), and dried over Na₂SO₄. The organic solvent was removed by evaporation. Purification by column chromatography in toluene/ethyl acetate (50:1 to 40:1) afforded 3.01 g of pure amide (99%) as a white solid. This compound

is known.¹ ¹H NMR (400 MHz, CDCl₃, ppm) δ 10.73 (*s*, 1H) 8.94 (*dd*, *J* = 7.8 Hz, *J* = 1.4 Hz, 1H) 8.85–8.81 (*m*, 1H) 8.19–8.13 (*m*, 1H) 8.06–8.00 (*m*, 2H) 7.61–7.49 (*m*, 4H) 7.48–7.43 (*m*, 1H) 1.38 (*s*, 9H).



Methyl 4-(quinolin-8-ylcarbamoyl)benzoate: 8-Aminoquinoline (1.44 g, 10 mmol) and triethylamine (1.8 mL, 13 mmol) were dissolved in anhydrous CH₂Cl₂ (30 mL) in a 50 ml round-bottom flask followed by dropwise addition of the acid chloride solution in CH₂Cl₂ (10 mL) through cannula. The acid chloride was prepared from monomethyl terephthalate (2.34 g, 13 mmol).² The reaction mixture was stirred overnight. After completion, the reaction was diluted with CH₂Cl₂ (25 mL), washed by aqueous HCl (15 mL, 1N), NaHCO₃ (15 mL of saturated aqueous solution), brine (25 mL), and dried over Na₂SO₄. The organic solvent was removed by evaporation. Purification by column chromatography in toluene/ethyl acetate (30:1) afforded 2.56 g of pure amide (84%) as a light yellow solid. This compound is known.¹ ¹H NMR (400 MHz, CDCl₃, ppm) δ 10.78 (*s*, 1H) 8.92 (*dd*, *J* = 6.9 Hz, *J* = 1.4 Hz, 1H) 8.85 (*dd*, *J* = 4.0 Hz, *J* = 1.8 Hz, 1H) 8.24–8.10 (*m*, 5H) 7.64–7.53 (*m*, 2H) 7.48 (*dd*, *J* = 4.1 Hz, *J* = 8.3 Hz, 1H) 3.97 (*s*, 3H).



N-(3-Methoxybenzoyl)-8-aminoquinoline: 8-Aminoquinoline (2.17 g, 15 mmol) and triethyl amine (2.8 mL, 20 mmol) were dissolved in anhydrous CH₂Cl₂ (30 mL) in a 100 ml round-bottom flask followed by dropwise addition of 3-methoxybezoyl chloride solution in CH₂Cl₂ (10 mL) through cannula. The acid chloride was prepared from 3-methoxybenzoic acid (3.04 g, 20 mmol).² The reaction mixture was stirred overnight. After completion, the reaction was diluted with CH₂Cl₂ (25 mL), washed by aqueous HCl (15 mL, 1N), NaHCO₃ (15 mL of saturated aqueous solution), brine (25 mL), and dried over Na₂SO₄. The organic solvent was removed by evaporation. Purification by column chromatography in toluene/ethyl acetate (30:1) afforded 3.86 g of pure amide (92%) as a white solid. This compound is known.¹ ¹H NMR (MHz, CDCl₃, ppm) δ 10.74 (*s*, 1H) 8.93 (*dd*, *J* = 7.5 Hz, *J* = 1.2 Hz, 1H) 8.85 (*dd*, *J* = 4.0 Hz, *J* = 1.7 Hz,

1H) 8.19 (*dd*, *J* = 1.7 Hz, *J* = 8.0 Hz, 1H) 7.68–7.52 (*m*, 4H) 7.51–7.42 (*m*, 2H) 7.15-7.10 (*m*, 1H) 3.92 (*s*, 3H).



N-(3-Trifluoromethylbenzoyl)-8-aminoquinoline: 8-Aminoquinoline (1.44 g, 10 mmol) and triethyl amine (1.8 mL, 13 mmol) were dissolved in anhydrous CH₂Cl₂ (30 mL) in a 50 ml round-bottom flask followed by dropwise addition of 2-trifluoromethylbenzoyl chloride (2.68 g, 12.8 mmol) through syringe. The reaction mixture was stirred overnight. After completion, the reaction was diluted with CH₂Cl₂ (25 mL), washed by aqueous HCl (15 mL, 1N), NaHCO₃ (15 mL of saturated aqueous solution), brine (25 mL), and dried over Na₂SO₄. The organic solvent was removed by evaporation. Purification by column chromatography in toluene/ethyl acetate (20:1) afforded 3.05 g of pure amide (96%) as a white solid. This compound is known.³ ¹H NMR (400 MHz, CDCl₃, ppm) δ 10.83 (*s*, 1H) 8.95–8.87 (*m*, 2H) 8.37 (*s*, 1H) 8.33–8.25 (*m*, 2H) 7.87–7.81 (*m*, 1H) 7.73–7.67 (*m*, 1H) 7.67–7.60 (*m*, 2H) 7.56 (*dd*, *J* = 8.1 Hz, *J* = 4.1 Hz, 1H).



N-(2-Methylbenzoyl)-8-aminoquinoline: 8-Aminoquinoline (1.44 g, 10 mmol) and triethyl amine (1.8 mL, 13 mmol) were dissolved in anhydrous CH₂Cl₂ (30 mL) in a 50 ml round-bottom flask followed by dropwise addition of 2-methylbenzoyl chloride (2.04 g, 13.2 mmol) through syringe. The reaction mixture was stirred overnight. After completion, the reaction was diluted with CH₂Cl₂ (25 mL), washed by aqueous HCl (15 mL, 1N), NaHCO₃ (15 mL of saturated aqueous solution), brine (25 mL), and dried over Na₂SO₄. The organic solvent was removed by evaporation. Purification by column chromatography in toluene/ethyl acetate (40:1) afforded 2.78 g of pure amide (87%) as a white solid. This compound is known.¹ ¹H NMR (400 MHz, CDCl₃, ppm) δ 10.21 (*s*, 1H) 8.99–8.91 (*m*, 1H) 8.78 (*dd*, *J* = 4.1 Hz, *J* = 1.8 Hz, 1H) 8.19 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 7.66–7.72 (*m*, 1H) 7.53–7.64 (*m*, 2H) 7.46 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 7.66–7.72 (*m*, 2H) 2.61 (*s*, 3H).



N-(2-Naphthalenecarbonyl)-8-aminoquinoline: 8-Aminoquinoline (1.44 g, 10 mmol) and triethylamine (1.8 mL, 13 mmol) were dissolved in anhydrous CH₂Cl₂ (30 mL) in a 50 ml round-bottom flask followed by dropwise addition of the acid chloride solution in CH₂Cl₂ (10 mL) through cannula. The acid chloride was prepared from 2-naphthalenecarboxylic acid (2.24 g, 13 mmol).² The reaction mixture was stirred overnight. After completion, the reaction was diluted with CH₂Cl₂ (25 mL), washed by aqueous HCl (15 mL, 1N), NaHCO₃ (15 mL of saturated aqueous solution), brine (25 mL), and dried over Na₂SO₄. The organic solvent was removed by evaporation. Purification by column chromatography in toluene/ethyl acetate (30:1) afforded 2.14 g of pure amide (72%) as a light yellow solid. This compound is known.^{3 1}H NMR (500 MHz, CDCl₃, ppm) δ 10.95–10.85 (*s*, 1H) 9.00 (*dd*, *J* = 7.4 Hz, *J* = 1.2 Hz, 1H) 8.89 (*dd*, *J* = 4.0 Hz, *J* = 1.7 Hz, 1H) 8.61 (*s*, 1H), 8.21 (*dd*, *J* = 8.0 Hz, *J* = 1.7 Hz, 1H) 8.14 (*dd*, *J* = 8.6 Hz, *J* = 1.7 Hz, 1H) 8.07–8.04 (*m*, 1H) 8.00 (*d*, *J* = 8.6 Hz, 1H) 7.95–7.91 (*m*, 1H) 7.65–7.55 (*m*, 4H) 7.50 (*dd*, *J* = 4.0 Hz, *J* = 8.0 Hz, 1H).



N-(2-methylnicotinoyl)-8-aminoquinoline: 8-Aminoquinoline (1.44 g, 10 mmol), 2-methylnicotinic acid (2.74 g, 20 mmol), EDC (2.10 g, 11 mmol), and DMAP (2.44 g, 20 mmol) were placed in a 100 mL round bottom flask. Anhydrous CH₂Cl₂ (30 mL) was added at room temperature. Reaction mixture was allowed to stir for 48 hours. Reaction mixture was dry-sorbed on the silica gel and purified using column chromatography using hexanes/ethyl acetate (1:1 to 1:5) affording product as a tan solid (656 mg, 25%). $R_f = 0.54$ (SiO₂, toluene/EtOAc, 1:3), mp 138–140 °C (from hexanes/EtOAc). ¹H NMR (500 MHz, CDCl₃, ppm) δ 10.31–10.199 (*s*, 1H) 8.95–8.90 (*m*, 1H) 8.79 (*dd*, *J* = 4.0 Hz, *J* = 1.7 Hz, 1H) 8.65 (*dd*, *J* = 4.6 Hz, *J* = 1.7 Hz, 1H) 8.21 (*dd*, *J* = 8.6 Hz, *J* = 1.7 Hz, 1H) 7.98 (*dd*, *J* = 7.6 Hz, *J* = 1.7 Hz, 1H) 7.64–7.57 (*m*, 2H) 7.48 (*dd*, *J* = 8.6 Hz, *J* = 4.6 Hz, 1H) 7.29 (*dd*, *J* = 7.5 Hz, *J* = 4.6 Hz, 1H) 2.85 (*s*, 3H) . ¹³C NMR (125 MHz, CDCl₃, ppm) δ 166.9, 157.0, 150.9, 148.7, 138.8, 136.8, 135.5, 134.6, 132.3,

128.3, 127.7, 122.5, 122.1, 121.3, 117.0, 23.8. FT-IR (neat, cm⁻¹) v 3352, 1678, 1533, 1490, 1430. HRMS (ESI+): Calculated for C₁₆H₁₃N₃O [M]⁺ 263.1059 Found 263.1061.



N-(2-Methyl-3-furanoyl)-8-aminoquinoline: 8-Aminoquinoline (1.44 g, 10 mmol), 2-methyl-3furancarboxylic acid (2.52 g, 20 mmol), EDC (2.10 g, 11 mmol), and DMAP (2.44 g, 20 mmol) were placed in a 100 mL round bottom flask. Anhydrous CH₂Cl₂ (30 mL) was added at room temperature. Reaction mixture was allowed to stir for 48 hours. Reaction mixture was dry-sorbed on the silica gel and purified using column chromatography using toluene/ethyl acetate (30:1) affording product as a white solid (1.46 g, 58%). R_f = 0.54 (SiO₂, hexanes/EtOAc, 3:1), mp 92–94 °C (from hexanes/EtOAc). ¹H NMR (500 MHz, CDCl₃, ppm) δ 10.36–10.21 (*s*, 1H) 8.86 (*dd*, *J* = 7.4 Hz, *J* = 1.1 Hz, 1H) 8.82 (*dd*, *J* = 4.0 Hz, *J* = 1.7 Hz, 1H) 8.16 (*dd*, *J* = 8.6 Hz, *J* = 1.7 Hz, 1H) 7.59–7.53 (*m*, 1H) 7.53–7.48 (*m*, 1H) 7.45 (*dd*, *J* = 8.0 Hz, *J* = 4.0 Hz, 1H) 7.35 (*d*, *J* = 2.3 Hz, 1H) 6.82 (*d*, *J* = 2.3 Hz, 1H) 2.74 (*s*, 3H). ¹³C NMR (125 MHz, CDCl₃, ppm) δ 162.4, 157.9, 148.5, 140.8, 138.9, 136.7, 135.0, 128.3, 127.8, 122.0, 121.7, 117.0, 116.5, 109.2, 14.1. FT-IR (neat, cm⁻¹) v 3352, 1661, 1534, 1520, 1492. HRMS (ESI+): Calculated for C₁₅H₁₂N₂O₂ [M]⁺ 252.0899, Found 252.0901.



N-(1-Methyl-1-phenylethyl)picolinamide: Picolinic acid (2.15 g, 17.5 mmol) and triethylamine (5 mL, 35 mmol) were dissolved in CH₂Cl₂ (40 mL) in a 100 mL round-bottom flask. The resulting mixture was cooled to 0 °C followed by dropwise addition of ethyl chloroformate (1.7 mL, 17.5 mmol). The solution was stirred for 30 minutes followed by dropwise addition of cumylamine (1.36 g, 10 mmol) via syringe. The suspension was stirred for 1 hour. The reaction was warmed up to room temperature and stirred for another 24 hours. After completion, water (50 ml) was added to the reaction mixture and the layers were separated. The aqueous layer was extracted by CH₂Cl₂ (2 x 25 mL). The combined organic layers were dried over MgSO₄ and concentrated to remove the solvent. Purification by column choromatography in hexanes/ethyl acetate (2:1) gave 2.11 g of the desired amide (88%) as a colorless oil. This compound is known.¹ ¹H NMR (400 MHz, CDCl₃, ppm) δ 8.58–8.53(*m*, 1H) 8.42–8.53 (*m*, 1H) 8.14 (*d*, *J* = 7.8 Hz,

1H) 7.83 (*td*, J_t = 7.8 Hz, J_d = 1.8 Hz, 1H) 7.50–7.45 (*m*, 2H) 7.44–7.39 (*m*, 1H) 7.37–7.30 (*m*, 2H) 7.27–7.21 (*m*, 1H) 1.85 (*s*, 6H).



N-(1-Methyl-1-(4-fluorophenyl)ethyl)picolinamide: Picolinic acid (1.23 g, 10 mmol) and triethylamine (3 mL, 20 mmol) were placed in a 50 mL flask, followed addition of dry CH₂Cl₂ (30 mL). The resulting mixture was cooled to 0 °C followed by dropwise addition of ethyl chloroformate (1.14 g, 10 mmol). The solution was stirred for 30 minutes at 0 °C. After that, 1-(4-fluorophenyl)-1-methylethylamine (1.0 g, 6.5 mmol) was added in one portion via syringe and the suspension was allowed to warm up to the room temperature and stirred overnight. Reaction mixture was dry-absorbed on the silica gel and subjected to the column chromatography first eluting with pure CH₂Cl₂ and then with mixture of hexanes/EtOAc (9:1) affording 1.66 g (98%) of the product as a yellowish thick oil. This compound is known.¹ ¹H NMR (500 MHz, CDCl₃, ppm) δ 8.57 – 8.52 (*m*, 1H), 8.46 (*br s*, 1H), 8.12 (*d*, *J* = 8.0 Hz, 1H), 8.85 – 7.78 (*m*, 1H), 7.46 – 7.36 (*m*, 3H), 7.03 – 6.96 (*m*, 2H), 1.82 (*s*, 6H).

OPTIMIZATION OF REACTION CONDITIONS

General procedure for reactions without additives (entries 1,2 table S1): a 1-dram vial equipped with a stir bar was charged with *N*-(4-methoxybenzoyl)-8-aminoquinoline (70 mg, 0.25 mmol, 1 equiv), $Cu(OAc)_2$, NMP (1 mL) and morpholine (0.05 mL, 0.57 mmol, 2.3 equiv). For entry 2, the vial was filled with O₂. The resulting mixture was heated with stirring at 110 °C for 12h. After completion, the reaction mixture was cooled down to room temperature and diluted with ethyl acetate (5 mL). The solution was filtered through a pad of silicagel and washed with ethyl acetate (2 × 25 mL). The yield of reaction was determined by ¹H NMR using trimethoxybenzene as an internal standard.

General procedure for reactions using NMO oxidant (entries 3-6, table S1): a 1 dram vial equipped with a stir bar was charged with *N*-(4-methoxybenzoyl)-8-aminoquinoline (70 mg, 0.25 mmol, 1 equiv), Cu(OAc), and K₂CO₃ (34 mg, 0.25 mmol, 1 equiv, for entry 3) or Ag₂CO₃ (for entries 4-6). Inside the glove box, NMO (*N*-methylmorpholine *N*-oxide) (59 mg, 0.5 mmol, 2 equiv) was added to the vial. Outside the glove box, NMP (1 mL) and morpholine (0.05 mL, 0.57 mmol, 2 equiv) were added to the resulting mixture. The vial was wrapped with aluminum foil (entries 4-6) and stirred at 110 °C for 14h 30 min (entries 4, 5) or 12h (entries 3, 6). For entries 4, 5: after completion, the reaction mixture was dry absorbed on the silica gel followed by purification by column chromatography in hexanes/ethyl acetate (3:1 to 2:1). For entries 3, 6: after completion, the reaction mixture was cooled down to room temperature, diluted by ethyl acetate (5 mL). The solution was filtered through a pad of silicagel, and washed with ethyl acetate (2 \times 25 mL). The yield of reaction was determined by ¹H NMR using trimethoxybenzene as an internal standard.

Table S1. Optimization of reaction conditions



Entry	x equiv.	Oxidant	Additive	Solvent	% yield
1	1	-		NMP	39%*
2	0.5	O ₂		NMP	51%*
3	0.25	NMO	K ₂ CO ₃	NMP	44%*
4	0.25	NMO	Ag_2CO_3 (0.25 equiv)	NMP	74%
5	0.1	NMO	Ag_2CO_3 (0.13 equiv)	NMP	87%
6	0.05	NMO	Ag ₂ CO ₃ (0.075 equiv)	NMP	80%*

*¹H NMR yield

AMINATION OF BENZOIC ACID DERIVATIES

General procedure: To a 1-dram vial equipped with a stir bar was added amide (0.5 mmol, 1 equiv), $Cu(OAc)_2$ (0.1–0.25 equiv) and Ag_2CO_3 (0.125–0.25 equiv). Inside the glove box, NMO (2 equiv) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (2 equiv) were added to the resulting mixture. The vial was wrapped with aluminum foil and stirred at 110 °C for indicated time. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography provided the desired product.



N-(2-Morpholino-4-methoxybenzoyl)-8-aminoquinoline (Table 2, entry 1): To a 1-dram vial equipped with stir bar was added *N*-4-methoxybenzoyl-8-aminoquinoline (139 mg, 0.5 mmol), Cu(OAc)₂ (9 mg, 0.05 mmol), and Ag₂CO₃ (17 mg, 0.06 mmol). Inside the glove box, NMO (118 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (*N*-methylpyrrolidone, 2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 13 h 30 min. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1 to 2:1) gave 158 mg (87%) of product as a white solid. $R_f = 0.16$ (SiO₂, hexanes/EtOAc, 3:1), mp 175-176 °C (from hexanes/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, ppm) δ 12.68–12.58 (*s*, 1H) 9.12 (*dd*, *J* = 7.3 Hz, *J* = 1.4 Hz, 1H) 8.88 (*dd*, *J* = 4.6 Hz, *J* = 1.8 Hz, 1H) 8.21–8.16 (*m*, 2H) 7.63–7.56 (*m*, 1H) 7.56–7.51 (*m*, 1H) 7.48 (*dd*, *J* = 8.2 Hz, *J* = 4.1 Hz,1H) 6.80–6.75 (*m*, 2H) 4.03–3.95 (*m*, 4H) 3.89 (*s*, 3H) 3.18–3.11 (*m*, 4H). ¹³C NMR (100 MHz, CDCl₃, ppm) 165.7, 163.1, 153.3, 148.4, 139.1, 136.7, 136.1, 134.4, 128.6, 127.9, 122.0, 121.8, 121.8, 117.9, 108.6, 106.4, 66.4, 55.8, 54.2 δ . FT-IR (neat, cm⁻¹) v 2973, 2934, 2846, 1652, 1518, 1485, 1109, 1033. HRMS (ESI+): Calculated for C₂₁H₂₁N₃O₃ [M+H]⁺ 364.1661, Found 364.1661.



N-(2-Morpholino-4-fluorobenzoyl)-8-aminoquinoline (Table 2, entry 2): To a 1-dram vial equipped with stir bar was added *N*-4-fluorobenzoyl-8-aminoquinoline (133 mg, 0.5 mmol), $Cu(OAc)_2$ (18 mg, 0.10 mmol), and Ag_2CO_3 (28 mg, 0.10 mmol). Inside the glove box, NMO (117 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 14 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel.

Purification by column chromatography in hexanes/ethyl acetate (4:1) gave 123 mg (70%) of product. $R_f = 0.32$ (SiO₂, hexanes/EtOAc, 3:1), mp 178-180 °C (from hexanes/EtOAc). ¹H NMR (500 MHz, CDCl₃, ppm) δ 12.51–21.44 (*s*, 1H) 9.10 (*dd*, *J* = 7.4 Hz, *J* = 1.7 Hz, 1H) 8.88 (*dd*, *J* = 4.0 Hz, *J* = 1.7 Hz, 1H) 8.23–8.15 (*m*, 2H) 7.63–7.53 (*m*, 2H) 7.50 (*dd*, *J* = 8.0 Hz, *J* = 4.0 Hz, 1H) 6.97–6.91 (*m*, 2H) 3.99–3.93 (*m*, 4H) 3.17–3.11 (*m*, 4H). ¹³C NMR (125 MHz, CDCl₃, ppm) δ 165.4 (*d*, *J*_{C-F} = 252.8 Hz), 165.1, 153.6 (*d*, *J*_{C-F} = 8.2 Hz), 148.5, 139.0, 136.8, 135.7, 134.7 (*d*, *J*_{C-F} = 10.0 Hz), 128.7, 127.9, 125.3 (*d*, *J*_{C-F} = 2.7 Hz), 122.1, 122.0, 118.0, 111.3 (*d*, *J*_{C-F} = 21.0 Hz) 107.0 (*d*, *J*_{C-F} = 22.8 Hz), 66.3, 54.1. ¹⁹F NMR (470 MHz, CDCl₃, ppm) δ -106.3 – -106.4 (m, 1F). FT-IR (neat, cm⁻¹) v 1646, 1520, 1484, 1110. HRMS (ESI+): Calculated for C₂₀H₁₈FN₃O₂ [M+H]⁺ 352.1461, Found 352.1460.



N-(2-Morpholino-4-*t*-butylbenzoyl)-8-aminoquinoline (Table 2, entry 3): To a 1-dram vial equipped with stir bar was added *N*-4-*t*-butylbenzoyl-8-aminoquinoline (152 mg, 0.5 mmol), Cu(OAc)₂ (11 mg, 0.06 mmol), and Ag₂CO₃ (17 mg, 0.06 mmol). Inside the glove box, NMO (117 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was wrapped with aluminum foil and stirred at 110 °C for 11 h 15 min. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (4:1) gave 158 mg (81%) of product as a tan solid. $R_f = 0.40$ (SiO₂, hexanes/EtOAc, 3:1), mp 142-144 °C (from hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃, ppm) δ 12.75–12.67 (*s*, 1H) 9.13 (*dd*, *J* = 7.8 Hz, *J* = 1.4 Hz, 1H) 8.87 (*dd*, *J* = 4.1 Hz, 1H) 7.31–7.26 (*m*, 2H) 4.03–3.93 (*m*, 4H) 3.21–3.15 (*m*, 4H) 1.37 (*s*, 9H) . ¹³C NMR (100 MHz, CDCl₃, ppm) δ 166.0, 156.3, 151.2, 148.4, 139.2, 136.7, 136.1, 132.3, 128.7, 127.9, 126.3, 121.9, 121.8, 118.0, 116.4, 66.5, 54.3, 35.6, 31.3. Signal for one carbon could not be located. FT-IR (neat, cm⁻¹) v 2961, 1660, 1526, 1486, 1112. HRMS (ESI+): Calculated for C₂₄H₂₇N₃O₂ [M+H]⁺ 390.2182, Found 390.2184.

Large scale synthesis: To a 6-dram vial equipped with stir bar was added *N*-4-*t*-butylbenzoyl-8aminoquinoline (1.52 g, 5.0 mmol), $Cu(OAc)_2$ (181 mg, 1.0 mmol), and Ag_2CO_3 (275 mg, 1.0 mmol). Inside the glove box, NMO (11.7 g, 10 mmol) was added to the vial. Outside the glove box NMP (10 mL) and morpholine (0.87 mL, 10 mmol) were added to the resulting mixture. The vial was wrapped with aluminum foil and stirred at 110 °C for 39 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (4:1) gave 1.55 g (80%) of product.



Methyl 3-morpholino-4-(quinolin-8-ylcarbamoyl)benzoate (Table 2, entry 4): To a 1-dram vial equipped with stir bar was added methyl 4-(quinolin-8-ylcarbamoyl)benzoate (153 mg, 0.5 mmol), Cu(OAc)₂ (18 mg, 0.10 mmol), and Ag₂CO₃ (28 mg, 0.10 mmol). Inside the glove box NMO (120 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was wrapped with aluminum foil and stirred at 110 °C for 14 h 30 min. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (2:1) gave 133 mg (68%) of product as a yellow solid. $R_f = 0.16$ (SiO₂, hexanes/EtOAc, 3:1), mp 183-184 °C (from hexanes/EtOAc). ¹H NMR (500 MHz, CDCl₃, ppm) δ 12.63–12.56 (*s*, 1H) 9.11 (*dd*, *J* = 7.4 Hz, *J* = 1.7 Hz, 1H) 8.88 (*dd*, *J* = 4.6 Hz, *J* = 1.7 Hz, 1H) 8.24–8.19 (*m*, 2H) 7.93–7.87 (*m*, 2H) 7.64–7.55 (*m*, 2H) 7.50 (*dd*, *J* = 8.6 Hz, *J* = 4.6 Hz, 1H) 4.00–3.93 (*m*, 7H) 3.22–3.16 (*m*, 4H). ¹³C NMR (100 MHz, CDCl₃, ppm) δ 166.7, 165.2, 151.3, 148.6, 139.1, 136.8, 135.5, 133.7, 133.1, 132.6, 128.6, 127.9, 125.4, 122.5, 122.1, 120.7, 118.1, 66.4, 54.1, 52.8. FT-IR (neat, cm⁻¹) v 2824, 1722, 1653, 1523, 1491, 1430, 1279, 1112. HRMS (ESI+): Calculated for C₂₂H₂₁N₃O₄ [M+H]⁺ 392.1610, Found 392.1612.



N-(2-Morpholino-5-methoxybenzoyl)-8-aminoquinoline (Table 2, entry 5): To a 1-dram vial equipped with stir bar was added *N*-(3-methoxybenzoyl)-8-aminoquinoline (139 mg, 0.50 mmol), $Cu(OAc)_2$ (11 mg, 0.06 mmol), and Ag_2CO_3 (18 mg, 0.06 mmol). Inside the glove box NMO (117 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added

to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 14 h 30 min. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (2:1) gave 149 mg (82%) of product as a tan solid. $R_f = 0.19$ (SiO₂, hexanes/EtOAc, 3:1), mp 148-151 °C (from hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃, ppm) δ 13.16–13.07 (*s*, 1H) 9.14 (*dd*, *J* = 7.3 Hz, *J* = 1.4 Hz, 1H) 8.90 (*dd*, *J* = 4.1 Hz, *J* = 1.4 Hz, 1H) 8.20 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 7.83 (*d*, *J* = 3.2 Hz, 1H) 7.64–7.53 (*m*, 2H) 7.50 (*dd*, *J* = 8.2 Hz, *J* = 4.6 Hz, 1H) 7.29–7.25 (*m*, 1H) 7.07 (*dd*, *J* = 8.7 Hz, *J* = 3.2 Hz, 1H) 4.06–3.99 (*m*, 4H), 3.88 (*s*, 3H) 3.14–3.08 (*m*, 4H). ¹³C NMR (100 MHz, CDCl₃, ppm) δ 165.5, 156.9, 148.4, 145.0, 139.3, 136.8, 136.1, 130.2, 128.7, 127.9, 122.2, 122.0, 121.7, 119.4, 118.5, 115.9, 66.6, 56.0, 54.6. FT-IR (neat, cm⁻¹) v 2843, 1651, 1528, 1488, 1282, 1262, 1114. HRMS (ESI+): Calculated for C₂₁H₂₁N₃O₃ [M+H]⁺ 364.1661, Found 364.1663.



N-(2-Morpholino 5-trifluoromethylbenzoyl)-8-aminoquinoline (Table 2, entry 6): To a 1-dram vial equipped with stir bar was added *N*-(3-trifluoromethylbenzoyl)-8-aminoquinoline (159 mg, 0.50 mmol), Cu(OAc)₂ (18 mg, 0.10 mmol), and Ag₂CO₃ (28 mg, 0.10 mmol). Inside the glove box, NMO (117 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 24 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1 to 2:1) gave 135 mg (67%) of an oil. R_f = 0.19 (SiO₂, hexanes/EtOAc, 3:1). ¹H NMR (400 MHz, CDCl₃, ppm) δ 12.41–12.31 (*s*, 1H) 9.12–9.07 (*m*, 1H) 8.90–8.84 (*m*, 1H) 8.41 (*s*, 1H) 8.24–8.18 (*m*, 1H) 8.24–7.70 (*m*, 1H) 7.65–7.55 (*m*, 2H) 7.51 (*dd*, *J* = 8.2 Hz, *J* = 4.1 Hz, 1H) 7.31 (*d*, *J* = 8.70 Hz, 1H) 3.98–3.92 (*m*, 4H) 3.24–3.17 (*m*, 4H). ¹³C NMR (125 MHz, CDCl₃, ppm) δ 164.8, 153.9, 148.6, 138.9, 136.9, 135.3, 129.9, 129.5, 129.3, 128.6, 127.9, 126.3 (*q*, *J*_{C-F} = 33.6 Hz), 124.2 (*q*, *J*_{C-F} = 271.0 Hz), 122.5, 122.1, 119.5, 118.0, 66.3, 53.9. ¹⁹F NMR (470 MHz, CDCl₃, ppm) δ -62.1 (s, 1F). FT-IR (neat, cm⁻¹) υ 3243, 2973, 1669, 1529, 1330, 1256, 1272, 1114, 1106, 1081. HRMS (ESI+): Calculated for C₂₁H₁₈F₃N₃O₂ [M+H]⁺ 402.1429, Found 402.1431.



N-(2-Morpholino-6-methylbenzoyl)-8-aminoquinoline (Table 2, entry 7): To a 1-dram vial equipped with stir bar was added *N*-(2-methylbenzoyl)-8-aminoquinoline (131 mg, 0.50 mmol), Cu(OAc)₂ (18 mg, 0.1 mmol), and Ag₂CO₃ (28 mg, 0.10 mmol). Inside the glove box NMO (117 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 14 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1) gave 122 mg (70%) of brown oil. R_f = 0.33 (SiO₂, hexanes/EtOAc, 3:1). ¹H NMR (500 MHz, CDCl₃, ppm) δ .10.68–10.58 (*s*, 1H) 9.00 (*dd*, *J* = 7.4 Hz, *J* = 1.1 Hz, 1H) 8.77 (*dd*, *J* = 4.0 Hz, *J* = 1.7 Hz, 1H) 8.19 (*dd*, *J* = 8.0 Hz, *J* = 1.7 Hz, 1H) 7.64–7.53 (*m*, 2H) 7.45 (*dd*, *J* = 8.0 Hz, *J* = 4.0 Hz, 1H) 7.31 (*t*, *J* = 8.0 Hz, 1H) 7.03–6.95 (*m*, 2H) 3.59–3.53 (*m*, 4H) 3.11–3.06 (*m*, 4H) 2.50 (*s*, 3H) .¹³C NMR (100 MHz, CDCl₃, ppm) δ 168.2, 150.3, 148.5, 138.8, 138.6, 136.7, 135.3, 132.1, 130.4, 128.5, 127.8, 126.2, 122.0, 122.0, 116.8, 116.7, 67.2, 53.3, 20.7. FT-IR (neat, cm⁻¹) v 3349, 2858, 2836, 1661, 1522, 1484, 1325, 1113. HRMS (ESI+): Calculated for C₂₁H₂₁N₃O₂ [M+H]⁺ 348.1712, Found 348.1713.



N-(1-Morpholino-2-napthalenecarbonyl)-8-aminoquinoline (Table 2, entry 8): To a 1-dram vial equipped with stir bar was added *N*-(2-naphthalenecarbonyl)-8-aminoquinoline (149 mg, 0.5 mmol), $Cu(OAc)_2$ (18 mg, 0.1 mmol), and Ag₂CO₃ (28 mg, 0.1 mmol). Inside the glove box NMO (117 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 24 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in toluene/ethyl acetate (20:1) gave 126 mg (66%) of product as a light brown solid. $R_f = 0.22$ (SiO₂, hexanes/EtOAc, 3:1), mp 214-216 °C (from

hexanes/EtOAc). ¹H NMR (500 MHz, CDCl₃, ppm) δ 12.74–12.64 (*s*, 1H), 9.18 (*dd*, *J* = 8.0 Hz, *J* = 1.1 Hz, 1H) 8.89 (*dd*, *J* = 4.0 Hz, *J* = 1.1 Hz, 1H) 8.71 (*s*, 1H) 8.21 (*dd*, *J* = 8.6 Hz, *J* = 1.7 Hz, 1H) 7.93 (*d*, *J* = 8.0 Hz, 1H) 7.82 (*d*, *J* = 8.0 Hz, 1H) 7.63 (*t*, *J* = 7.7 Hz, 1H) 7.59–7.52 (*m*, 3H) 7.52–7.44 (*m*, 2H) 4.03–3.96 (*m*, 4H) 3.31–31.21 (*m*, 4H) .¹³C NMR (100 MHz, CDCl₃, ppm) δ 166.0, 148.5, 148.2, 139.1, 136.7, 135.9, 135.6, 134.0, 130.2, 129.3, 128.8, 128.7, 128.4, 127.9, 127.1, 125.8, 122.2, 122.0, 118.1, 116.3, 66.5, 54.4. FT-IR (neat, cm⁻¹) υ 2927, 2858, 1667, 1523, 1485, 1326, 1114. HRMS (ESI+): Calculated for C₂₄H₂₁N₃O₂ [M+H]⁺ 384.1712, Found 384.1714.



N-(2-Methyl-6-morpholinonicotinoyl)-8-aminoquinoline (Table 2, entry 9): To a 1-dram vial equipped with stir bar was added N-(2-methylnicotinoyl)-8-aminoquinoline (132 mg, 0.50 mmol), $Cu(OAc)_2$ (22 mg, 0.12 mmol), and Ag₂CO₃ (34 mg, 0.12 mmol). Inside the glove box NMO (117 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 25 h. After completion, the reaction mixture was cooled down to room temperature, diluted with ethyl acetate (30 mL), extracted with H_2O (3 × 10 ml), and dried over Mg_2SO_4 . The organic solvent was removed by evaporation. Purification by column chromatography in the eluent system of toluene/ethyl acetate (1:3) with triethyl amine (1.6%) followed by drying under high vacuum to remove trace amounts of NMP gave 98 mg (56%) of a yellow oil. $R_f = 0.20$ (SiO₂, toluene/EtOAc, 3:1). ¹H NMR (500 MHz, CDCl₃, ppm) δ 10.58–10.47 (s, 1H), 8.96 (dd, J = 6.9 Hz, J = 1.7 Hz, 1H) 8.80 (dd, J = 4.0 Hz, J = 1.7 Hz, 1H) Hz, 1H) 8.41 (*d*, *J* = 5.7 Hz, 1H) 8.22 (*dd*, *J* = 8.0 Hz, *J* = 1.7 Hz, 1H) 7.67–7.56 (*m*, 2H) 7.49 (*dd*, *J* = 8.0 Hz, J = 4.0 Hz, 1H) 6.78 (d, J = 5.7 Hz, 1H) 3.61–3.55 (m, 4H) 3.24–3.19 (m, 4H) 2.69 (s, 3H).¹³C NMR (125 MHz, CDCl₃, ppm) δ 167.1, 158.4, 156.1, 150.9, 148.7, 138.6, 136.8, 134.7, 128.5, 127.8, 124.2, 122.5, 122.2, 117.0, 110.5, 66.6, 51.5, 23.7. FT-IR (neat, cm⁻¹) v 1670, 1574, 1523, 1484, 1452, 1327. 1116. HRMS (ESI+): Calculated for $C_{20}H_{20}N_4O_2$ [M+H]⁺ 349.1665, Found 349.1667.



N-(2-Methyl-4-morpholino-3-furanoyl)-8-aminoquinoline (Table 2, entry 10): To a 1-dram vial equipped with stir bar was added *N*-(2-methyl-3-furanoyl)-8-aminoquinoline (126 mg, 0.5 mmol), Cu(OAc)₂ (18 mg, 0.10 mmol), and Ag₂CO₃ (28 mg, 0.10 mmol). Inside the glove box NMO (117 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was stirred at 110 °C for 22 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in toluene/ethyl acetate (30:1 to 20:1) gave 96 mg (57%) of product as a tan solid. $R_f = 0.30$ (SiO₂, hexanes/EtOAc, 3:1), mp 184–185 °C (from hexanes/EtOAc). ¹H NMR (500 MHz, CDCl₃, ppm) δ11.87–11.77 (*s*, 1H) 9.04 (*dd*, *J* = 7.4 Hz, *J* = 1.1 Hz, 1H) 8.91 (*dd*, *J* = 4.6 Hz, *J* = 1.7 Hz, 1H) 8.18 (*dd*, *J* = 8.0 Hz, *J* = 1.1 Hz, 1H) 7.60–7.51 (*m*, 2H) 7.49 (*dd*, *J* = 8.6 Hz, *J* = 4.6 Hz, 1H) 7.17 (*s*, 1H) 4.02–3.94 (*m*, 4H) 3.07–3.00 (*m*, 4H) 2.66 (*s*, 3H). ¹³C NMR (125 MHz, CDCl₃, ppm) δ162.7, 159.5, 148.4, 139.3, 139.3, 136.7, 136.1, 130.0, 128.5, 127.8, 121.9, 121.8, 117.7, 112.4, 66.8, 54.6, 14.7. FT-IR (neat, cm⁻¹) v 3137, 2922, 1667, 1602, 1526, 1323, 1263, 1113. HRMS (ESI+): Calculated for C₁₉H₁₉N₃O₃ [M+H]⁺ 338.1505, Found 338.1507.

AMINATION OF BENZYLAMINE DERIVATIES



N-(1-Methyl-1(-2-morpholinophenyl)ethyl)picolinamide (Scheme 1) To a 10 mL pressure-vessel equipped with stir bar was added *N*-(1-methyl-1-phenylethyl)picolinamide (120 mg, 0.5 mmol), $Cu(OAc)_2$ (23 mg, 0.12 mmol), and Ag_2CO_3 (34 mg, 0.12 mmol). Inside the glove box, K_3PO_4 (212 mg, 1.0 mmol) and NMO (117 mg, 1.0 mmol) were added to the vial. Outside the glove box DMSO (dimethyl sulfoxide, 2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was stirred at 130 °C for 36 h 30min. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in toluene/ethyl

acetate (10:1 to 5:1) gave 70 mg (43%) of a yellow oil. $R_f = 0.17$ (SiO₂, hexanes/EtOAc, 3:1). ¹H NMR (500 MHz, CDCl₃, ppm) δ 8.92–8.85 (*s*, 1H) 8.57–8.53 (*m*, 1H) 8.08 (*d*, *J* = 7.4 Hz, 1H) 7.79 (*td*, *J_t* = 7.4 Hz, *J_d* = 1.7 Hz, 1H) 7.58 (*dd*, *J* = 8.0 Hz, *J* = 1.7 Hz, 1H) 7.39 (*ddd*, *J* = 7.4 Hz, *J* = 4.6 Hz, *J* = 1.1 Hz, 1H) 7.33 (*dd*, *J* = 8.0 Hz, *J* = 1.1 Hz, 1H) 7.31–7.26 (*m*, 1H) 7.25–7.19 (*m*, 1H) 3.86–3.76 (*m*, 2H) 3.76–3.68 (*m*, 2H) 2.94 (*td*, *J_t* = 11.5 Hz, *J_d* = 2.9 Hz, 2H) 2.53 (*d*, *J* = 12.0 Hz, 2H) 1.99 (*s*, 6H). ¹³C NMR (125 MHz, CDCl₃, ppm) δ 162.8, 151.7, 151.0, 148.0, 143.1, 137.7, 128.5, 127.7, 126.5, 126.2, 125.8, 122.2, 67.7, 53.4, 54.5, 29.2. FT-IR (neat, cm⁻¹) v 2955, 2934, 2858, 1676, 1510, 1454, 1431, 1112. HRMS (ESI+): Calculated for C₁₉H₂₃N₃O₂ [M+H]⁺ 326.1869, Found 326.1866.



N-(1-Methyl-1-(4-fluoro-2-morpholinophenyl)ethyl)picolinamide (Scheme 1): To a 10 mL pressurevessel equipped with stir bar was added N-(1-methyl-1-(4-fluorophenyl)ethyl)picolinamide (127 mg, 0.49 mmol), Cu(OAc)₂ (23 mg, 0.12 mmol), and Ag₂CO₃ (34 mg, 0.12 mmol). Inside the glove box, K_3PO_4 (212 mg, 1.0 mmol) and NMO (117 mg, 1.0 mmol) were added to the vial. Outside the glove box DMSO (2 mL) and morpholine (0.09 mL, 1.03 mmol) were added to the resulting mixture. The vial was stirred at 130 °C for 38 h 40min. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (2:1) gave 67 mg (40%) of a yellow oil. $R_f = 0.14$ (SiO₂, hexanes/EtOAc, 3:1). ¹H NMR (500 MHz, CDCl₃, ppm) δ 8.85–8.78 (s, 1H) 8.57–8.53 (m, 1H) 8.10 (d, J = 8.0 Hz, 1H) 7.79 (td, $J_t = 7.4$ Hz, $J_d = 1.1$ Hz, 1H) 7.55 (*dd*, *J* = 8.6 Hz, *J* = 6.9 Hz, 1H) 7.40 (*dd*, *J* = 6.9 Hz, *J* = 5.1 Hz, 1H) 7.03 (*dd*, *J* = 2.9 Hz, *J* = 10.3 Hz, 1H) 6.94–6.87 (*m*, 1H) 3.84–3.75 (*m*, 2H) 3.75–3.68 (*m*, 2H) 2.90–2.78 (*m*, 2H) 2.58–2.46 (*m*, 2H) 1.96 (s, 6H). ¹³C NMR (125 MHz, CDCl₃, ppm) δ 162.6 (d, J_{C-F} = 248.2 Hz), 162.8, 153.4 (d, J_{C-F} = 6.4 Hz), 150.8, 148.0, 139.1 (d, J_{C-F} = 3.6 Hz), 137.7, 129.1 (d, J_{C-F} = 9.1 Hz), 126.3, 122.2, 113.3 (d, J_{C-F} = 21.0 Hz), 112.9 (d, $J_{C-F} = 19.2$ Hz), 67.5, 54.9, 54.5, 29.2. FT-IR (neat, cm⁻¹) v 3374, 2964, 2928, 2852, 2822, 1673, 1587, 1612, 1498, 1261, 1157, 1113. HRMS (ESI+): Calculated for C₁₉H₂₂FN₃O₂ [M+H]⁺ 344.1774, Found 344.1769

AMINATION OF PRIMARY AND SECONDARY AMINES

General procedure: To a 1-dram vial equipped with stir bar was added amide (0.5 mmol), Cu(OAc)₂ (0.126-0.25 equiv), and Ag₂CO₃ (0.126-0.25 equiv). Inside the glove box, NMO (*N*-methylmorpholine-

N-oxide) (2.0 equiv.) was added to the vial. Outside the glove box NMP (2 mL) and amine (2 equiv) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating to 110 °C and stirring for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography gave the desired product.



N-(2-N-Methylbenzylamino-4-methoxybenzoyl)-8-aminoquinoline (Table 3, entry 1): To a 1-dram vial equipped with stir bar was added N-4-methoxybenzoyl-8-aminoquinoline (139 mg, 0.5 mmol), Cu(OAc)₂ (23 mg, 0.125 mmol), and Ag₂CO₃ (34 mg, 0.125 mmol). Inside the glove box, NMO (118 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and N-methylbenzylamine (121 mg, 1.00 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1) gave 164 mg (82%) of product as a tan oil. $R_f = 0.43$ (SiO₂, hexanes/EtOAc, 3:1). ¹H NMR (400 MHz, CDCl₃, ppm) δ 13.78 (s, 1H) 9.09 (dd, J = 7.8 Hz, J = 0.9 Hz, 1H) 8.75 (dd, J = 1.8 Hz, J = 1.8 Hz, 1H) 8.27 (s, J = 8.7 Hz, 1H) 8.16 (dd, J = 8.7 Hz, J = 1.8 Hz, 1H) 7.60 (t, J = 8.2 Hz, 1H) 7.51 (dd, J = 8.2 Hz, J = 0.9 Hz, 1H) 7.42 (dd, J = 8.2 Hz, J = 4.1 Hz, 1H) 7.29–7.26 (m, 2H) 7.13–7.11 (m, 2)3H) 6.74 (dd, J = 8.7 Hz, J = 2.7 Hz, 1H) 6.67 (d, J = 2.3 Hz, 1H) 4.33 (s, 2H) 3.79 (s, 3H) 3.93 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, ppm) δ165.0, 162.4, 152.4, 148.2, 139.6, 136.4, 136.2, 133.6, 129.7, 128.3, 128.1, 127.7, 127.4, 121.9, 121.4, 121.2, 117.5, 109.1, 108.6, 61.2, 55.4, 43.7. Signal for one carbon could not be located. FT-IR (neat, cm-1) v 3022, 1653, 1599, 1526, 1487, 1324, 1246. HRMS (ESI+): Calculated for $C_{25}H_{23}N_3O_2 [M+H]^+$ 398.1869, Found 398.1870.



N-(2-N-Methylpropylamino-4-methoxybenzoyl)-8-aminoquinoline (Table 3, entry 2): To a 1-dram vial equipped with stir bar was added N-4-methoxybenzoyl-8-aminoquinoline (139 mg, 0.5 mmol), Cu(OAc)₂ (23 mg, 0.125 mmol), and Ag₂CO₃ (34 mg, 0.125 mmol). Inside the glove box NMO (118 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and N-methylpropylamine (73 mg, 1.0 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1) gave 129 mg (74%) of product as a clear oil. $R_f = 0.51$ (SiO₂, hexanes/EtOAc, 3:1). ¹H NMR (400 MHz, CDCl₃, ppm) δ 14.11 (s, 1H) 9.08 (dd, J = 7.8 Hz, J = 1.4 Hz, 1H) 8.82 (dd, J = 4.1 Hz, J = 1.8 Hz, 1H) 8.34 (d, J = 8.7 Hz, 1H) 8.13 (dd, J = 8.2 Hz, J = 1.8 Hz, 1H) 7.57 (t, J = 7.8 Hz, 1H) 7.48 (*dd*, *J*= 7.8 Hz, *J* = 0.9 Hz, 1H) 7.42 (*dd*, *J*= 8.2 Hz, *J* = 4.1 Hz, 1H) 6.85 (*d*, *J*= 2.3 Hz, 1H) 6.81 (*dd*, *J* = 8.7 Hz, J = 2.3 Hz, 1H) 3.87 (s, 3H) 3.12–3.08 (m, 2H) 2.88 (s, 3H) 1.63 (sextet, J = 7.8 Hz, 2H) 0.82 (t, J= 7.8 Hz, 3H).¹³C NMR (100 MHz, CDCl₃, ppm) δ 164.9, 162.7, 153.5, 148.0, 139.8, 136.6, 136.1, 133.6, 128.3, 127.6, 122.4, 121.4, 121.1, 117.6, 109.2, 108.5, 59.1, 55.5, 44.6 20.2, 12.0. FT-IR (neat, cm-1) v 2970.3, 1651.3, 1599.1, 1526.2, 1487.1, 1251.3, 1219.3. HRMS (ESI+): Calculated for $C_{21}H_{23}N_{3}O_{2}[M+H]^{+}$ 350.1869, Found 350.1867.



N-(2-Ethyl isonipecotato-4-methoxybenzoyl)-8-aminoquinoline (Table 3, entry 3): To a 1-dram vial equipped with stir bar was added *N*-4-methoxybenzoyl-8-aminoquinoline (139 mg, 0.5 mmol), $Cu(OAc)_2$ (12 mg, 0.063 mmol), and Ag_2CO_3 (17 mg, 0.063 mmol). Inside the glove box, NMO (118 mg, 1.0 mmol)

was added to the vial. Outside the glove box NMP (2 mL) and ethyl isonipecotate (157 mg, 1.00 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature, diluted with dichloromethane (2 mL), and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1) gave 149 mg (69%) of product as white solid. $R_f = 0.34$ (SiO₂, hexanes/EtOAc, 3:1), mp 185–188 °C (from hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃, ppm) δ 12.72 (*s*, 1H) 9.15 (*dd*, *J* = 7.8 Hz, *J* = 1.4 Hz, 1H) 8.89 (*dd*, *J* = 4.1 Hz, *J* = 1.8 Hz, 1H) 8.20 (*d*, *J* = 8.7 Hz, 1H) 8.15 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 7.58 (*t*, *J* = 7.8 Hz, 1H) 7.51 (*dd*, *J* = 7.6 Hz, *J* = 1.4 Hz, 1H) 7.45 (*dd*, *J* = 8.2Hz, *J* = 4.1 Hz, 1H) 6.76–6.73 (*m*, 2H) 4.04 (*q*, *J* = 7.3 Hz, 1H) 3.87 (*s*, 3H) 3.41 (*d*, *J* = 11.9 Hz, 2H) 2.84 (*td*, *J*_t = 11.9 Hz, *J_d* = 2.3 Hz, 2H) 2.40 (*tt*, *J* = 11.00 Hz, *J* = 3.7 Hz, 2H) 2.28 (*qd*, *J_q* = 11.0 Hz, *J_d* = 3.7 Hz, 2H) 2.00 (*dd*, *J* = 12.8 Hz, *J* = 2.7 Hz, 2H) 1.15 (*t*, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃, ppm) δ 174.8, 165.6, 162.8, 153.9, 148.3, 139.0, 136.4, 136.2, 134.0, 128.4, 127.6, 121.5, 121.4, 117.8 108.2, 106.5, 60.4, 55.6, 54.0, 41.0, 27.7, 14.3. FT-IR (neat, cm-1) υ 3186, 2967, 2925, 1734, 1655, 1596, 1520, 1256, 1164, 1047. HRMS (ESI+): Calculated for C₂₅H₂₇N₃O₄ [M+H]⁺ 434.2080, Found 434.2079.



N-(2-4-Cyanopiperidino 4-methoxybenzoyl)-8-aminoquinoline (Table 3, entry 4): To a 1-dram vial equipped with stir bar was added *N*-4-methoxybenzoyl-8-aminoquinoline (139 mg, 0.5 mmol), Cu(OAc)₂ (12 mg, 0.063 mmol), and Ag₂CO₃ (17 mg, 0.063 mmol). Inside the glove box NMO (118 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and 4-cyanopiperidine (110 mg, 1.00 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1) gave 137 mg (71%) of product as a light yellow solid. $R_f = 0.21$ (SiO₂, hexanes/EtOAc, 3:1), mp 155–156 °C (from hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃, ppm) δ 12.56 (*s*, 1H) 9.16 (*dd*, *J* = 7.8 Hz, *J* = 1.8 Hz, 1H) 8.21 (*d*, *J* = 8.7, 1H) 8.20 (*dd*, *J* = 8.2 Hz, *J* = 1.8 Hz, 1H) 7.60 (*t*, *J* = 7.8 Hz, 1H) 7.54 (*dd*, *J* = 7.8 Hz, *J* = 1.4 Hz, 1H) 7.50 (*dd*, *J* = 8.2 Hz, *J* = 4.1 Hz, 1H) 6.77–

6.75 (*m*, 2H) 3.88 (*s*, 3H) 3.35–3.32 (*m*, 2H) 3.01 (*s*, 2H) 2.73 (*s*, 1H) 2.30 (*s*, 2H) 2.24 (*s*, 2H). ¹³C NMR (100 MHz, CDCl₃, ppm) δ 165.4, 162.9, 153.2, 147.9, 138.9, 136.7, 135.9, 134.2, 128.5, 127.7, 121.8, 121.6, 121.5, 118.0, 108.8, 106.6, 55.6, 52.5, 28.1, 26.1 Signal for one carbon could not be located. FT-IR (neat, cm-1) υ 3180, 2825, 1660, 1597, 1519, 1489, 1270, 1254. HRMS (ESI+): Calculated for C₂₃H₂₂N₄O₂ [M+H]⁺ 387.1821, Found 387.1822.



N-(4-Piperidone etheyleneketalato-4-methoxybenzoyl)-8-aminoquinoline (Table 3, entry 5): To a 1dram vial equipped with stir bar was added N-4-methoxybenzoyl-8-aminoquinoline (139 mg, 0.5 mmol), Cu(OAc)₂ (12 mg, 0.063 mmol), and Ag₂CO₃ (17 mg, 0.063 mmol). Inside the glove box NMO (118 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and 4-piperidone ethylene ketal (143 mg, 1.00 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1) gave 171 mg (82%) of product as a light yellow solid. $R_f = 0.22$ (SiO₂, hexanes/EtOAc, 3:1), mp 186–189 °C (from hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃, ppm) δ 12.94 (s, 1H) 9.16 (dd, J = 7.8 Hz, J = 1.4 Hz, 1H) 8.93 (dd, J = 4.6 Hz, J = 1.8 Hz, 1H) 8.24 (d, J = 8.7 Hz, 1H) 8.16 (*dd*, *J*= 8.2 Hz, *J* = 1.8 Hz, 1H) 7.57 (*t*, *J* = 8.2 Hz, 1H) 7.51 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 7.47 (dd, J = 8.2 Hz, J = 4.1 Hz, 1H) 6.84 (d, J = 2.3 Hz, 1H) 6.77 (dd, J = 8.7 Hz, J = 2.3 Hz, 1H) 3.96 (s, J = 2.3 Hz, 1H)4H) 3.87 (s, 3H) 3.21 (t, J = 5.5 Hz, 4H) 2.12 (s, 4H). ¹³C NMR (100 MHz, CDCl₃, ppm) δ 165.6, 162.9, 153.8, 148.1, 139.2, 136.4, 136.3, 134.0, 128.4, 127.6, 121.7, 121.6, 121.5, 118.0, 109.0, 107.2, 106.7, 64.4, 55.6, 52.6, 34.6. FT-IR (neat, cm-1) υ 2934, 2837, 1650, 1600, 1521, 1487, 1257, 1143, 1096. HRMS (ESI+): Calculated for $C_{24}H_{25}N_3O_4$ [M+H]⁺ 420.1923, Found 420.1923.



N-(tert-Butylpiperidin-4-ylcarbamate-4-methoxybenzoyl)-8-aminoquinoline (Table 3, entry 6): To a 1-dram vial equipped with stir bar was added N-4-methoxybenzoyl-8-aminoquinoline (139 mg, 0.5 mmol), Cu(OAc)₂ (23 mg, 0.125 mmol), and Ag₂CO₃ (34 mg, 0.125 mmol). Inside the glove box, NMO (118 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and tert-butylpiperidin-4ylcarbamate (200 mg, 1.00 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in tolene/ethyl acetate (10:1 to 10:3) gave 196 mg (83%) of product as a light green solid. $R_f = 0.24$ (SiO₂, hexanes/EtOAc, 3:1), mp 175–177 °C (from hexanes/EtOAc). ¹H NMR (400 MHz, $CDCl_3$, ppm) δ 12.62 (s, 1H) 9.13 (dd, J = 7.8 Hz, J = 1.4, 1H) 8.84 (dd, J = 4.1 Hz, J = 1.4 Hz, 1H) 8.19 (*dd*, *J*= 8.2 Hz, *J* = 1.8 Hz, 1H) 8.15 (*d*, *J* = 8.7 Hz, 1H) 7.59 (*t*, *J* = 8.2 Hz, 1H) 7.53 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 7.49 (dd, J = 8.2 Hz, J = 4.6 Hz, 1H) 6.75-6.72 (m, 2H) 4.24 (d, J = 5.9 Hz, 1H) 3.87 (s, 3H) 3.61 (s, 1H) 3.36 (d, J=11.9 Hz, 2H) 2.91 (t, J=10.5 Hz, 2H) 2.03 (d, J=11.0 Hz, 2H) 1.88 (qd, $J_a=1.0$ Hz, 2H) 1.88 (qd, J_a=1.0 Hz 11.0 Hz, $J_d = 3.7$ Hz, 2H) 1.41 (s, 9H). ¹³C NMR (100 MHz, CDCl₃, ppm) δ 165.7, 162.8, 155.2, 153.6, 147.7 139.0, 136.6, 136.1, 134.0, 129.1, 128.5, 128.3, 127.8, 121.6, 121.5, 118.0, 108.1, 106.3, 79.5, 55.6, 53.1, 31.9. 28.5. FT-IR (neat, cm-1) v 3416, 2979, 2822, 1708, 1658, 1601, 1520, 1488, 1256, 1236, 1174, 1029. HRMS (ESI+): Calculated for $C_{27}H_{32}N_4O_4$ [M]⁺ 477.2502, Found 477.2498.



N-(2-Cyclohexylamino-5-trifluoromethylbenzoyl)-8-aminoquinoline (Table 3, entry 7): To a 1-dram vial equipped with stir bar was added *N*-3-trifluoromethylbenzoyl-8-aminoquinoline (158 mg, 0.5 mmol), Cu(OAc)₂ (23 mg, 0.125 mmol), and Ag₂CO₃ (34 mg, 0.125 mmol). Inside the glove box, NMO (118 mg,

1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and cyclohexylamine (99 mg, 1.00 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (10:1) gave 83 mg (40%) of product as a light yellow solid. $R_f = 0.32$ (SiO₂, hexanes/EtOAc, 10:1), mp 162–164 °C (from hexanes). ¹H NMR (400 MHz, CDCl₃, ppm) δ 10.59 (*s*, 1H) 8.86 (*dd*, *J* = 6.0 Hz, *J* = 1.4 Hz, 1H) 8.77 (*dd*, *J* = 6.9 Hz, *J* = 1.8 Hz, 1H) 8.19 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 8.16 (*s*, 1H) 7.99 (*d*, *J* = 1.4 Hz, 1H) 7.61–7.48 (*m*, 4H) 6.80 (*d*, *J* = 8.7 Hz, 1H) 3.48–3.40 (*m*, 2H) 2.07-2.04 (*m*, 1H) 1.82-1.79 (*m*, 2H) 1.67–1.64 (*m*, 1H) 1.46–1.25 (*m*, 5H).¹³C NMR (100 MHz, CDCl₃, ppm) δ 167.5, 151.4, 148.6, 138.9, 136.5, 134.5, 129.8, 128.1, 127.4, 125.8, 124.9 (*q*, *J*_{C-F} = 269.9 Hz) 121.9, 116.6, 115.7 (*q*, *J*_{C-F} = 32.4 Hz) 114.3, 112.0, 50.9, 32.7, 35.9, 24.8. Signal for one carbon could not be located. ¹⁹F NMR (470 MHz, CDCl₃, ppm) δ 57.7. FT-IR (neat, cm-1) ν 3349, 2928, 2858, 1653, 1536, 1324, 1107, 1085. HRMS (ESI+): Calculated for C₂₃H₂₂F₃N₃O [M+H]⁺ 414.1793, Found 414.1788.



N-(2-Cyclooctylamino-5-trifluoromethylbenzoyl)-8-aminoquinoline (Table 3, entry 8): To a 1-dram vial equipped with stir bar was added *N*-3-trifluoromethylbenzoyl-8-aminoquinoline (158 mg, 0.5 mmol), Cu(OAc)₂ (23 mg, 0.125 mmol), and Ag₂CO₃ (34 mg, 0.125 mmol). Inside the glove box, NMO (118 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and cyclooctylamine (0.127 g, 1.00 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (3:1) gave 114 mg (52%) of product as a light orange solid. $R_f = 0.38$ (SiO₂, hexanes/EtOAc, 10:1), mp 118–120 °C (from hexanes). ¹H NMR (400 MHz, CDCl₃, ppm) δ 10.59 (*s*, 1H) 8.87 (*dd*, *J* = 4.1 Hz, *J* = 1.8 Hz, 1H) 8.77 (*dd*, *J* = 6.9 Hz, *J* = 1.4 Hz, 1H) 8.19 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 7.99 (*d*, *J* = 0.9 Hz, 1H) 7.61–7.53 (*m*, 3H) 7.49 (*dd*, *J* = 8.2 Hz, *J* = 4.1 Hz, 1H) 6.72 (*d*, *J* = 9.2 Hz, 1H) 3.68–3.60 (*m*, 1H) 1.98–1.91 (*m*, 2H) 1.82–1.55 (*m*, 13H).¹³C NMR (100 MHz, CDCl₃, ppm) δ 167.5, 151.2, 148.6, 138.9, 136.5, 134.6, 129.9, 128.1, 127.4, 125.8, 124.9 (*q*, *J*_{C-F} = 269.9 Hz), 121.9, 116.6,

115.6 (q, J_{C-F} = 33.6 Hz), 114.4, 112.2, 52.2, 32.2, 27.2, 25.8, 24.0. Signal for one carbon could not be located. ¹⁹F NMR (470 MHz, CDCl₃, ppm) δ 57.7. FT-IR (neat, cm-1) υ 3355, 2931, 2855, 1651, 1531, 1488, 1324, 1273, 1109, 1082. HRMS (ESI+): Calculated for C₂₅H₂₆F₃N₃O [M+H]⁺ 442.2106, Found 442.2101.



N-(2-Neopentylamino-5-trifluoromethylbenzoyl)-8-aminoquinoline (Table 3, entry 9): To a 1-dram vial equipped with stir bar was added N-3-trifluoromethylbenzoyl-8-aminoquinoline (158 mg, 0.5 mmol), Cu(OAc)₂ (23 mg, 0.125 mmol), and Ag₂CO₃ (34 mg, 0.125 mmol). Inside the glove box NMO (118 mg, 1.0 mmol) was added to the vial. Outside the glove box NMP (2 mL) and neopentylamine (87 mg, 1.00 mmol) were added to the resulting mixture. The vial was stirred at room temperature for 5 minutes followed by heating at 110 °C for 12 h. After completion, the reaction mixture was cooled down to room temperature and dry absorbed on silica gel. Purification by column chromatography in hexanes/ethyl acetate (10:1) gave 65 mg (32%) of product as a light yellow solid. $R_f = 0.77$ (SiO₂, hexanes/EtOAc, 3:1), mp 148–150 °C (from hexanes). ¹H NMR (400 MHz, CDCl₃, ppm) δ 10.62 (s, 1H) 8.86 (dd, J = 4.1 Hz, J = 1.2 Hz, 1H) 8.80 (*dd*, *J* = 7.3 Hz, *J* = 1.4 Hz, 1H) 8.49–8.38 (*m*, 1H) 8.18 (*dd*, *J* = 8.2 Hz, *J* = 1.4 Hz, 1H) 8.00 (s, 1H) 7.61–7.51 (m, 3H) 7.48 (dd, J = 8.4 Hz, J = 4.6 Hz, 1H) 6.80 (d, J = 8.7 Hz, 1H) 3.02 (d, J = 5.0 Hz, 2H) 1.07 (s, 9H). ¹³C NMR (100 MHz, CDCl₃, ppm) δ 167.7, 153.2, 148.8, 139.1, 136.7, 134.8, 130.2, 128.3, 127.6, 125.7 (q, J_{C-F} = 3.6 Hz), 125.1 (q, J_{C-F} = 270.4 Hz), 122.1, 122.0, 116.8, 116.0 $(q, J_{C-F} = 32.9 \text{ Hz})$ 114.3, 111.8, 55.2, 32.3, 28.1. ¹⁹F NMR (470 MHz, CDCl₃, ppm) δ -60.82. FT-IR (neat, cm-1) v 3346, 2961, 1654, 1533, 1430, 1324, 1103, 1084. HRMS (ESI+): Calculated for $C_{22}H_{22}F_{3}N_{3}O[M+H]^{+}$, Found.

AUXILIARY CLEAVAGE



2-Morpholino-4-*t***-butylbenzoic acid**: A 10 mL Kontes flask equipped with a stir bar was charged with *N*-(2-morpholino-4-*t*-butylbenzoyl)-8-aminoquinoline (97 mg, 0.25 mmol), NaOH (150 mg, 3.75 mmol) and EtOH (1 mL). The resulting mixture was stirred at 130 °C for 3 days. After completion, the reaction mixture was cooled down to room temperature, diluted by 50 mL ethyl acetate and washed by HCl (4 × 20 mL of 0.5N aqueous solution). The aqueous layers were combined and extracted with ethyl acetate (3 × 15 mL).Combined organic layers were dried over MgSO₄. Evaporation to remove organic solvent gave 60 mg (91%) of pure acid as a light brown solid. This compound is known.⁴ ¹H NMR (500 MHz, CDCl₃, ppm) δ 8.22 (*d*, *J* = 8.0 Hz, 1H) 7.45 (*d*, *J* = 8.6 Hz, 1H) 7.43 (*s*, 1H) 3.97 (*brs*, 4H) 3.10 (*brs*, 4H) 1.35 (*s*, 9H).

CONTROL EXPERIMENTS

General procedure: To a 1-dram vial equipped with stir bar was added *N*-4-methoxybenzoyl-8aminoquinoline (70 mg, 0.5 mmol), $Cu(OAc)_2$ (6 mg, 0.03 mmol), and Ag_2CO_3 (9 mg, 0.03 mmol). Inside the glove box, NMO (59 mg, 0.50 mmol) was added to the vial. Outside the glove box NMP (1 mL) and morpholine (0.05 mL, 0.57 mmol) were added to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 15 h. After completion, the reaction mixture was cooled to room temperature and diluted with ethyl acetate (5 mL). The solution was filtered through a pad of silicagel and washed with ethyl acetate (2 × 25 mL). The yield of reaction was determined by ¹H NMR using trimethoxybenzene as an internal standard.



DIAMINATION: To a 1-dram vial equipped with stir bar was added *N*-(4-piperidone-etheyleneketalato 4-methoxybenzoyl)-8-aminoquinoline (43 mg, 0.10 mmol), $Cu(OAc)_2$ (5 mg, 0.03 mmol), and Ag_2CO_3 (7 mg, 0.03 mmol). Inside the glove box, NMO (23 mg, 0.20 mmol) was added to the vial. Outside the glove box NMP (0.5 mL) and morpholine (0.02 mL, 0.23 mmol) were added to the resulting mixture. The vial was wrapped by aluminum foil and stirred at 110 °C for 14 h. After completion, the reaction mixture was cooled down to room temperature, diluted by ethyl acetate (5 mL), filtered through silica gel and washed by ethyl acetate (25 mL × 2 times). The solvent was evaporated under reduced pressure and analysis by ¹H NMR showed no diaminated product.

< 2%

REFERENCES

- 1. Tran, L. D.; Popov, I.; Daugulis, O. J. Am. Chem. Soc. 2012, 134, 18237.
- 2. Tran, L. D.; Daugulis, O. Angew. Chem. Int. Ed. 2012, 51, 5188.
- 3. Ano, Y.; Tobisu, M.; Chatani, N. Org. Lett. 2012, 14, 354.

No Cu(OAc)₂

4. Yoo, E. J.; Ma, S.; Mei, T.-S.; Chan, K. S. L.; Yu, J.-Q. J. Am. Chem. Soc. 2011, 133, 7652.















































































































